Research Alliance Corporation III is a blank check company formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses... Show more
Research Alliance Corporation III is a special purpose acquisition company (SPAC) incorporated in 2026 and headquartered in New York, New York. The blank-check company was formed to effect a merger, share exchange, asset acquisition, or similar business combination with one or more businesses, with a stated focus on the healthcare and life sciences sectors. RACC is sponsored by an affiliate of RA Capital Management, L.P., a leading life sciences-focused investment firm with a strong track record in biotech SPAC transactions. The company completed its initial public offering on May 20, 2026, raising $75 million by selling 7.5 million Class A ordinary shares at $10.00 per share. RACC is led by CEO Matthew Hammond, Ph.D., a partner at RA Capital, and Chief Business Officer Henry Stusnick.
RACC shares have experienced an extraordinary rally over the past 30 days, climbing from approximately $10.80 on July 8, 2026 to $24.62 at the close on August 6, 2026 — a gain of roughly 128%. Prior to the rally, the stock had traded in a narrow range between $10.21 and $11.20 for the first two months following its IPO, with daily volume often measuring only a few thousand shares. The breakout began in late July and accelerated sharply as trading volumes surged from an average of roughly 8,000 shares per day to well over 100,000 shares during the peak of the move. For the quarter, RACC has appreciated approximately 146% from its $10.00 IPO price, reflecting both the initial post-IPO stability and the dramatic re-rating following the business combination announcement.
The overwhelming catalyst for RACC's 30-day surge was the July 27, 2026 announcement of a definitive business combination agreement with Oak Hill Bio (OHB Pediatrics Ltd.), a clinical-stage rare disease biotechnology company. Oak Hill Bio is developing rugonersen, an investigational antisense oligonucleotide (ASO) therapy designed to treat Angelman syndrome by restoring neuronal UBE3A expression — a mechanism that could address the root cause of this devastating neurodevelopmental disorder. The drug is currently in the pivotal Phase 3 BEACON clinical trial, which dosed its first patient in July 2026.
The deal terms proved highly attractive to investors: approximately $175 million in gross proceeds, with $75 million from RACC's trust account fully backstopped by RA Capital and $100 million in committed private financing, including a $45 million SAFE investment from RA Capital at signing and an oversubscribed $55 million PIPE priced at $10.00 per share. PIPE participants include prominent biotech investors such as Balyasny Asset Management, Janus Henderson Investors, BVF Partners, and venBio. The presence of elite life sciences investors, a clear clinical catalyst in the BEACON trial, and a cash runway projected through a Phase 3 readout and potential NDA submission in 2029 all contributed to the sharp price appreciation. Additionally, the combined company's planned Nasdaq listing under the ticker OAKH generated further speculative interest.
Over the broader quarter, RACC's performance reflects the distinct phases of a pre-deal SPAC transitioning into a high-profile merger target. From its May 20 IPO through late July, shares traded near the $10.00 trust value, exhibiting the low volatility and thin volume typical of SPACs searching for a target. The quiet period expired on June 29, 2026, but no analyst coverage emerged during that window. The quarter's defining event was the Oak Hill Bio deal announcement, which transformed RACC from an under-the-radar blank-check company into one of the most actively traded SPACs on the Nasdaq. The transaction structure — featuring a fully backstopped trust by RA Capital and participation from marquee biotech funds — reassured investors that the deal had strong institutional backing, mitigating redemption risk and fueling the sustained upward move through early August.
For traders and investors looking to complement their own research with data-driven strategies, Tickeron's Trending AI Robots page offers a curated view of the platform's top-performing AI-powered trading bots. Tickeron hosts hundreds of AI robots that actively trade thousands of tickers across various strategies, timeframes, and performance profiles. The Trending AI Robots section narrows the field to only those bots demonstrating the strongest recent results and highest relevance in current market conditions. Each bot operates with its own defined trading methodology — ranging from short-term momentum plays to longer-duration trend-following approaches — allowing users to find strategies aligned with their own investment style. Exploring this section can help investors identify systematic approaches to navigating fast-moving names and shifting market dynamics.
Looking ahead, several key factors will shape RACC's trajectory. The primary near-term catalyst is the filing and eventual effectiveness of the S-4 registration statement with the SEC, which will contain the proxy statement and prospectus for the shareholder vote on the proposed business combination. Shareholder approval and the level of redemptions from RACC's trust account will be closely watched — though the fully backstopped trust by RA Capital provides a meaningful buffer. On the clinical front, updates on enrollment progress in the Phase 3 BEACON trial for rugonersen, as well as any interim data readouts, could significantly influence sentiment. Competitive dynamics also matter: Ultragenyx's GTX-102 and IONS' ION582 are both in Phase 3 development for Angelman syndrome, making the race to market a critical narrative. Broader macro factors — including Federal Reserve policy, biotech sector sentiment, and SPAC market conditions — will also play a role as the deal moves toward its expected year-end 2026 close.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows